Teva Breaks Out OTC Sales Figures In Bid To Play Up Diversification
This article was originally published in The Tan Sheet
Teva Pharmaceutical Industries reported OTC product sales for the first time Feb. 15. The Jerusalem firm said OTC net revenue was $765 million in 2011, up 54.2% and attributable largely to the acquisition of German firm ratiopharm and the PGT Healthcare joint venture with Procter & Gamble.
You may also be interested in...
Bristol-Myers exec to head Teva; GSK’s Witty now Sir Andrew; ISPE names Berg president; more People In Brief.
PGT Healthcare CEO Briain de Buitleir and COO Eli Shani say the joint venture will help Teva realize greater value for its localized OTCs and enable Procter & Gamble to expand its nutritional products portfolio.
NaZura BioHealth, spun out from Elcelyx Therapeutics, will market its Lovidia weight-loss product in 2014 when it launches into the direct-response channel, before potential suitors get serious about acquiring the brand.